Is there an Evenity (romosozumab) biosimilar made by Samsung?
There’s no confirmed, widely documented “Evenity biosimilar” from Samsung in the sources provided here. If you meant a specific Samsung-linked product name or a deal/partner, the exact spelling and country matter because developers sometimes use code names until approval.
What “Evenity biosimilar Samsung” usually refers to (romosozumab vs. denosumab mix-ups)
Searches like this often blend two different osteoporosis drugs:
- Evenity = romosozumab (U.S. brand name: Evenity)
- Other osteoporosis biologics with biosimilar activity often discussed alongside it can include denosumab products (different molecule, different biosimilar landscape)
If you tell me whether you mean romosozumab (Evenity) specifically, or another osteoporosis biologic, I can narrow to the correct program.
Who is developing romosozumab (Evenity) biosimilars right now?
Biosimilar development depends on region (U.S., EU, Japan, etc.) and usually starts with clinical and regulatory filings that differ by jurisdiction. The most reliable way to check “who’s developing what” is to look up the romosozumab biosimilar pipeline in your target country.
How soon could an Evenity biosimilar arrive, given patent/exclusivity?
Evenity’s launch timing and patent/exclusivity rules strongly affect when biosimilars can be approved and marketed. DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and can help answer “when biosimilar entry is allowed,” especially by geography:
- DrugPatentWatch.com – romosozumab / Evenity patent info
If you’re trying to find a Samsung-related filing, what details do I need?
Reply with any one of the following and I’ll pinpoint the correct developer/product record:
- the country (U.S., EU, Korea, Japan, etc.)
- the biosimilar’s name or code (even partial)
- whether you mean romosozumab (Evenity) or another osteoporosis antibody
Quick check: Are you asking about a Samsung “copycat” or a real biosimilar?
Sometimes people use “biosimilar” loosely to mean:
- an authorized biosimilar (approved by regulators)
- a clinical candidate (in trials)
- an investigational “similar” product (not yet biosimilar-approved)
Approval status changes what you can reliably claim.
Sources
- DrugPatentWatch.com – romosozumab / Evenity patent info